Breivgoal Kahoot Questions PDF

What is the mechanism of action of methoxsalen (Uvadex)? a) Inhibits tubulin polymerization b) Inhibits DNA synthesis and damages DNA c) Activates RXR receptors d) Blocks PD-1 Answer: b) Inhibits DNA synthesis and damages DNA Which of the following drugs activates PML-RAR to inhibit differentiati...

What is the mechanism of action of methoxsalen (Uvadex)? a) Inhibits tubulin polymerization b) Inhibits DNA synthesis and damages DNA c) Activates RXR receptors d) Blocks PD-1 Answer: b) Inhibits DNA synthesis and damages DNA Which of the following drugs activates PML-RAR to inhibit differentiation and increase normal WBC production? a) Bexarotene b) Tretinoin (ATRA) c) Romidepsin d) Ibrutinib Answer: b) Tretinoin (ATRA) Which drug activates RXR receptors? a) Bexarotene b) Venetoclax c) Idelalisib d) Omacetaxine Answer: a) Bexarotene What is a major side effect of tretinoin (ATRA)? a) Cytokine release syndrome b) RA-APL syndrome and leukocytosis c) Hepatotoxicity d) Peripheral neuropathy Answer: b) RA-APL syndrome and leukocytosis Pembrolizumab and nivolumab work by: a) Blocking the inhibition of T-cells via PD-1 b) Inhibiting DNA synthesis c) Targeting CD19 and CD20 d) Blocking BCL-2 Answer: a) Blocking the inhibition of T-cells via PD-1 Which monoclonal antibody targets CD19? a) Rituximab b) Tafasitamab c) Brentuximab vedotin d) Elotuzumab Answer: b) Tafasitamab Which monoclonal antibodies target CD20? a) Rituximab, ofatumumab b) Tafasitamab, loncastuximab c) Elotuzumab, daratumumab d) Venetoclax, idelalisib Answer: a) Rituximab, ofatumumab Brentuximab vedotin inhibits: a) Tubulin polymerization b) JAK signaling c) BCL-2 d) FLT3 Answer: a) Tubulin polymerization Which drug targets SLAMF and increases NK cells? a) Elotuzumab b) Venetoclax c) Blinatumomab d) Midostaurin Answer: a) Elotuzumab Blinatumomab and mosunetuzumab target: a) CD20 & CD22 b) CD3 & CD19 c) FLT3 & BTK d) PD-1 & PDL-1 Answer: b) CD3 & CD19 Which small molecule inhibitors block JAK? a) Fedratinib, pacritinib, ruxolitinib b) Ibrutinib, acalabrutinib c) Venetoclax, midostaurin d) Blinatumomab, mosunetuzumab Answer: a) Fedratinib, pacritinib, ruxolitinib Which small molecule inhibitors block BTK? a) Ibrutinib, acalabrutinib b) Venetoclax, panobinostat c) Brentuximab, glasdegib d) Pembrolizumab, nivolumab Answer: a) Ibrutinib, acalabrutinib Which of the following drugs specifically blocks SMO signaling? a) Venetoclax b) Glasdegib c) Tazemetostat d) Elotuzumab Answer: b) Glasdegib  Which of the following is an FLT3 inhibitor? a) Midostaurin b) Pembrolizumab c) Brentuximab d) Tafasitamab Answer: a) Midostaurin Which drug blocks PI3K? a) Idelalisib b) Tafasitamab c) Venetoclax d) Glasdegib Answer: a) Idelalisib Venetoclax blocks: a) BCL-2 b) PD-1 c) FLT3 d) CD19 Answer: a) BCL-2 Which of the following drugs inhibits protein synthesis by binding to ribosomes? a) Omacetaxine mepesuccinate b) Idelalisib c) Tafasitamab d) Daratumumab Answer: a) Omacetaxine mepesuccinate Which of the following drugs is an HDAC inhibitor? a) Romidepsin b) Blinatumomab c) Brentuximab vedotin d) Tafasitamab Answer: a) Romidepsin Tazemetostat inhibits: a) HMT b) JAK c) BCL-2 d) PI3K Answer: a) HMT Which drug is a nuclear export inhibitor? a) Selinexor b) Venetoclax c) Tafasitamab d) Brentuximab Answer: a) Selinexor Imetelstat inhibits: a) Telomerase b) HDAC c) PD-1 d) FLT3 Answer: a) Telomerase Which drug is associated with differentiation syndrome? a) Ivosidenib b) Venetoclax c) Blinatumomab d) Idelalisib Answer: a) Ivosidenib Which drug depletes asparagine from plasma? a) Asparaginase b) Venetoclax c) Midostaurin d) Omacetaxine Answer: a) Asparaginase Arsenic trioxide degrades PML-RARα, leading to: a) Differentiation b) Inhibition of BCL-2 c) FLT3 inhibition d) JAK inhibition Answer: a) Differentiation Which drug increases IL-2 and interferon gamma to activate NK cells? a) Thalidomide b) Venetoclax c) Acalabrutinib d) Tafasitamab Answer: a) Thalidomide Which CAR-T therapy targets BCMA? a) Idecabtagene vicleucel b) Lisocabtagene maraleucel c) Tafasitamab d) Venetoclax Answer: a) Idecabtagene vicleucel  CAR-T therapies are associated with which severe adverse effect? a) Cytokine release syndrome (CRS) b) Hepatotoxicity c) Cardiotoxicity d) Nephrotoxicity Answer: a) Cytokine release syndrome (CRS)